Abcellera Biologics

ABCL

#369

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. The company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.

How is Abcellera Biologics (ABCL) performing?

Abcellera Biologics (ABCL) is up 4.2% today, trading at $11.40 with a daily range of $10.53 to $11.47. Over the past year, Abcellera Biologics hit a 52-week high of $11.47 and a low of $2.73, and is up 235.1% year-to-date.

What is the market cap of Abcellera Biologics (ABCL)?

Abcellera Biologics (ABCL) has a market cap of $3.48B. To see how ABCL compares to other stocks, check out CoinGecko's list of stocks ranked by market cap.

Who are the different issuers of tokenized Abcellera Biologics (ABCL)?

Robinhood Europe is the only issuer of tokenized Abcellera Biologics on CoinGecko. Their token, ABCL, has a market cap of $64.87.

Where can I buy tokenized Abcellera Biologics (ABCL)?

Tokenized Abcellera Biologics (ABCL) is currently not available to trade on any exchanges listed on CoinGecko. Check back later — information will be updated when trading activity resumes.